Replies to post #4721 on Dendreon Corp fka DNDNQ

[walldiver]

The MS in TAX327 for asymptomatic pts was 23.0 months. Even if the MS for the GVAX arm is 30.7 months, there is still a 20% chance it won't be stat sig superior to Tax. VITAL-1 was powered and designed at a time when CEGE believed the MS target to beat was 18.9 months. In addition, all of the Phase 2 pts were at Johns Hopkins, and got excellent supportive care. I don't think the same will occur at the other trial centers. Lastly, I don't think allogenic cancer immunotherapeutics work. None have worked yet in any randomized trial. So we'll see.